Filtered By:
Condition: Ischemic Stroke
Countries: Australia Health
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 193 results found since Jan 2013.
The effects of endovascular clot retrieval and thrombolysis on dysphagia in an Australian quaternary hospital: A retrospective review
CONCLUSION: This study identified ongoing high rates of dysphagia amongst this patient population regardless of treatment type, demonstrating the need for ongoing SLP management post stroke. Further research is required in this area to develop an evidence-base for SLPs and the wider medical team and to inform clinical practice guidelines.WHAT THIS PAPER ADDS: What is already known on the subject Stroke is one of the leading causes of disability and death internationally. Dysphagia (impaired swallowing), a common sequalae of stroke, is known to contribute to decreased quality of life, increased length of hospital stay and m...
Source: International Journal of Language and Communication Disorders - November 12, 2021 Category: Speech-Language Pathology Authors: Ellie Minchell Anna Rumbach Emma Finch Source Type: research
Cerebrovascular Disease Profiles of Culturally and Linguistically Diverse Communities in South Western Sydney and New South Wales
Conclusion: Greater rates of TIA/stroke were observed in specific CALD communities, with increased rates of cerebrovascular risk factors. Culturally specific, targeted interventions may bridge health inequalities in cerebrovascular disease.Cerebrovasc Dis
Source: Cerebrovascular Diseases - May 12, 2022 Category: Neurology Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Depression Is More than a Stigma
Manoj K. Pandey is Lecturer in Economics, Australian National University; Vani S. Kulkarni is Lecturer in Sociology, University of Pennsylvania; and Raghav Gaiha is (Hon. ) Professorial Research Fellow, Global Development Institute, University of ManchesterBy Manoj K. Pandey, Vani S. Kulkarni and Raghav GaihaCanberra, Philadelphia and Manchester, Mar 20 2019 (IPS) Depression is often distinguished from other non-communicable diseases or NCDs (e.g., cancer, diabetes, cardio-vascular diseases, hypertension) because of the stigma attached to it. Among other consequences, those suffering from depression are often denied access...
Source: IPS Inter Press Service - Health - March 20, 2019 Category: International Medicine & Public Health Authors: Manoj K. Pandey - and Raghav Gaiha Tags: Featured Global Headlines Health Human Rights TerraViva United Nations Women's Health Source Type: news
Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome
In conclusion the detection of complement activation products on circulating erythrocytes and platelets using a highly sensitive and specific assay further supports the view that APS is a complement-mediated disorder. Increased EC4d and PC4d percentages are associated with the active inflammatory disease in SLE. It is difficult to translate this finding to APS which is a non-acute inflammatory disorder. We failed to find an association with both the classification and non-classification criteria, including thrombocytopenia. However, we believe that this sensitive tool to evaluate complement activation may offer more inform...
Source: Frontiers in Immunology - April 11, 2019 Category: Allergy & Immunology Source Type: research
Underusage of Oral Anticoagulation in Atrial Fibrillation: Can We Prevent More Strokes?
Atrial fibrillation (AF) is the most common sustained arrhythmia in Australia, affecting 2% of the population, and 6% of those over the age of 55 years [1]. The greatest contributor to morbidity and mortality in AF is its association with ischaemic stroke [2]. AF increases the risk of cardioembolic stroke five-fold, with an annual incidence of up to 7% [3]. There have been several validated tools developed to help individualise stroke risk, such as the CHADS2 [4], CHA2DS2-VASc [5], and more recently the CHA2DS2-VA score [6], all of which require the input of several vascular risk factors.
Source: Heart, Lung and Circulation - June 2, 2021 Category: Cardiology Authors: Karan Rao, Ravinay Bhindi Tags: Editorial Source Type: research
Persistent pathology of the patent foramen ovale: a review of the literature
Med J Aust. 2021 Jul 4. doi: 10.5694/mja2.51141. Online ahead of print.ABSTRACTA patent foramen ovale (PFO) is an interatrial shunt, with a prevalence of 20-34% in the general population. While most people do not have secondary manifestations of a PFO, some reported sequelae include ischaemic stroke, migraine, platypnoea-orthodeoxia syndrome and decompression illness. Furthermore, in some cases, PFO closure should be considered for patients before neurosurgery and for patients with concomitant carcinoid syndrome. Recent trials support PFO closure for ischaemic stroke patients with high risk PFOs and absence of other identi...
Source: Medical Journal of Australia - July 4, 2021 Category: General Medicine Authors: Kenneth K Cho Shaun Khanna Phillip Lo Daniel Cheng David Roy Source Type: research
